Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CALCIOZ-K27 is a combination nutritional supplement marketed by Chemross Lifesciences, primarily indicated for the management of bone-related disorders such as osteoporosis, osteomalacia, and calcium deficiency. The product is typically formulated as a softgel capsule containing Calcium (often as Calcium Citrate Maleate), Vitamin K2-7 (Menaquinone-7), and Vitamin D3 (Cholecalciferol). Calcium serves as a fundamental mineral for maintaining bone density and structural integrity. Vitamin D3 acts as a Vitamin D receptor agonist to enhance intestinal calcium absorption and regulate calcium homeostasis. Vitamin K2-7 serves as a critical cofactor for the enzyme gamma-glutamyl carboxylase, which activates osteocalcin, a protein essential for binding calcium to the bone matrix. This synergistic combination aims to improve bone mineralization while reducing the risk of ectopic vascular calcification.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on CALCIOZ-K27.